Dear Partners,
The CDC endorsed the Advisory Committee on Immunization Practices’ (ACIP) recommendation that the Novavax COVID-19 vaccine be used as an option for adults ages 18 years and older. CDC Director Dr. Rochelle Walensky endorsed that recommendation and released a statement Yesterday, Western States Scientific Safety Review Workgroup (WSSSRW) recommended the use of Novavax.
The Novavax COVID-19 vaccine is the first COVID-19 protein subunit vaccine recommended for use in the United States. Having multiple types of vaccines offers more options and flexibility for people receiving COVID-19 vaccines, as well as jurisdictions and vaccine providers.
The Novavax COVID-19 vaccine’s safety and effectiveness have been confirmed by clinical research and by the thousands of people who have already received it. As occurs for all vaccines—including all COVID-19 vaccines—safety monitoring will continue for the Novavax vaccine.
The Novavax COVID-19 vaccine is administered as a two-dose primary series, with the doses given 3-8 weeks apart for adults 18 years and older.
Providers may begin ordering Novavax next week. The minimum order is 100 doses, and no diluent is required. Complete Novavax product details are available on myCAvax.
Resources:
